From: Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact?
Metformin (n = 7) | Controls (n = 7) | p value | |
---|---|---|---|
Male Gender | 3 (43) | 3 (43) | 1 |
Age (years) | 53.3 ± 7.8 | 52.9 ± 7.4 | 0.918 |
Weight (kg) | 99.4 ± 25.6 | 79.9 ± 11.6 | 0.091 |
BMI (kg/m2) | 34.1 ± 8.8 | 28.0 ± 3.5 | 0.118 |
Blood Pressure (mm Hg) | |||
Systolic | 131.4 ± 9.0 | 140 ± 15.3 | 0.225 |
Diastolic | 85.0 ± 5.8 | 85.0 ± 7.6 | 1.000 |
Serum creatinine (mg/dl) | 1.51 ± 0.36 | 1.54 ± 0.40 | 0.875 |
eGFR (mL/min per 1·73 m2)a | 48.1 ± 11.1 | 48.0 ± 15.5 | 0.994 |
Haemoglobin (g/dl) | 14.5 ± 2.3 | 13.4 ± 1.3 | 0.298 |
Urine proteins (g/24 h) | 0 [0; 3990] | 131 [0; 350] | 0.143 |
Fasting serum glucose (mmol/L) | 118.7 ± 17.6 | 91.3 ± 9.7 | 0.012 |
Blood pressure lowering drugs (n) | 1.71 ± 0.8 | 1.71 ± 1.0 | 1 |
ACE- ARBs use | 6 (86) | 6 (86) | 1 |